Morgan Stanley I Teos Therapeutics, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 429,340 shares of ITOS stock, worth $4.36 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

429,340

Previous 251,131 70.96%

Holding current value

$4.36 Million

Previous $1.5 Million 185.52%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$5.04 - $10.2 $898,173 - $1.82 Million	178,209 Added 70.96%	429,340 $4.28 Million
Q1 2025 May 15, 2025	BUY	$5.97 - $8.15 $3,068 - $4,189	514 Added 0.21%	251,131 $1.5 Million
Q4 2024 Feb 14, 2025	SELL	$7.22 - $10.02 $1.81 Million - $2.51 Million	-250,749 Reduced 50.01%	250,617 $1.92 Million
Q3 2024 May 14, 2025	SELL	$10.09 - $17.97 $5.93 Million - $10.6 Million	-587,933 Reduced 53.97%	501,366 $5.12 Million
Q3 2024 Nov 14, 2024	SELL	$10.09 - $17.97 $5.93 Million - $10.6 Million	-587,933 Reduced 53.97%	501,366 $5.12 Million
Q2 2024 May 14, 2025	BUY	$10.33 - $18.09 $8.66 Million - $15.2 Million	838,682 Added 334.65%	1,089,299 $16.2 Million
Q2 2024 Oct 17, 2024	SELL	$10.33 - $18.09 $5.61 Million - $9.82 Million	-543,057 Reduced 33.27%	1,089,299 $16.2 Million
Q2 2024 Aug 14, 2024	SELL	$10.33 - $18.09 $5.61 Million - $9.82 Million	-543,057 Reduced 33.27%	1,089,299 $16.2 Million
Q1 2024 Oct 17, 2024	BUY	$9.89 - $13.64 $5.37 Million - $7.41 Million	543,057 Added 49.85%	1,632,356 $22.3 Million
Q1 2024 Aug 16, 2024	BUY	$9.89 - $13.64 $4.95 Million - $6.83 Million	500,863 Added 44.27%	1,632,356 $22.3 Million
Q1 2024 May 15, 2024	BUY	$9.89 - $13.64 $4.95 Million - $6.83 Million	500,863 Added 44.27%	1,632,356 $22.3 Million
Q4 2023 Aug 16, 2024	BUY	$8.57 - $11.06 $361,602 - $466,665	42,194 Added 3.87%	1,131,493 $12.4 Million
Q4 2023 Feb 13, 2024	BUY	$8.57 - $11.06 $7.45 Million - $9.62 Million	869,740 Added 332.28%	1,131,493 $12.4 Million
Q3 2023 Nov 15, 2023	BUY	$10.95 - $14.6 $931,549 - $1.24 Million	85,073 Added 48.15%	261,753 $2.87 Million
Q2 2023 Aug 14, 2023	SELL	$12.93 - $18.05 $5 Million - $6.98 Million	-386,534 Reduced 68.63%	176,680 $2.34 Million
Q1 2023 May 15, 2023	SELL	$13.02 - $22.62 $3.69 Million - $6.42 Million	-283,645 Reduced 33.49%	563,214 $7.67 Million
Q4 2022 Feb 14, 2023	BUY	$17.77 - $21.6 $230,388 - $280,044	12,965 Added 1.55%	846,859 $16.5 Million
Q3 2022 Nov 14, 2022	SELL	$18.6 - $27.25 $4.08 Million - $5.98 Million	-219,340 Reduced 20.83%	833,894 $15.9 Million
Q2 2022 Oct 27, 2022	BUY	$16.57 - $35.1 $4.16 Million - $8.81 Million	250,864 Added 31.27%	1,053,234 $21.7 Million
Q2 2022 Aug 15, 2022	BUY	$16.57 - $35.1 $4.16 Million - $8.81 Million	250,864 Added 31.27%	1,053,234 $21.7 Million
Q1 2022 Oct 27, 2022	SELL	$31.92 - $47.45 $8.01 Million - $11.9 Million	-250,864 Reduced 23.82%	802,370 $25.8 Million
Q1 2022 May 13, 2022	BUY	$31.92 - $47.45 $20.4 Million - $30.3 Million	638,371 Added 389.25%	802,370 $25.8 Million
Q4 2021 Feb 14, 2022	BUY	$26.23 - $47.86 $193,865 - $353,733	7,391 Added 4.72%	163,999 $7.64 Million
Q3 2021 Nov 15, 2021	BUY	$23.91 - $29.58 $3.74 Million - $4.63 Million	156,608 New	156,608 $4.23 Million

Others Institutions Holding ITOS

# of Institutions

139

Shares Held

37.7M

Call Options Held

733K

Put Options Held

611K

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $361M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account